Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Glucagon-like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectrum : a Publication of the American Diabetes Association, American Diabetes Association, Aug
Whilst early Phase 2 data suggest favourable effects on blood pressure and lipid profiles, the drug has also been associated with dose-dependent increases in resting heart rate
Liu Qiang, Chairman of YaoPharma, said: "By leveraging Pfizer's exceptional global development experience and commercialisation network, along with YaoPharma's profound expertise in small molecule R&D and manufacturing, our shared goal is to accelerate the global development and commercialisation of this innovative drug, thereby benefiting patients worldwide more rapidly and extensively." Pfizers moves with Metsera and now YaoPharma add to continued competition in the obesity drug market, which has also seen Teva Pharmaceuticals gain US Food and Drug Administration (FDA) approval in August of a generic GLP-1 of its version of Novo Nordisks injectable Saxenda (liraglutide).
Although Novo Nordisk recently announced a price cut for Wegovy (in response to competition from Eli Lillys Zepbound), costs remain highwith significant impacts on both self-funded employers and individuals interested in the benefits of GLP-1s
US$ 25.76
US$ 27.52
US$ 19.99
US$ 20.87
US$ 28.35
US$ 28.51
US$ 25.51
US$ 24.19
US$ 24.92
US$ 25.92
US$ 27.32
US$ 22.79
US$ 20.43
US$ 21.13
US$ 28.96
US$ 28.64
US$ 27.37
